Obesity Management

Early time-restricted eating was more effective for losing weight than eating over a window of ≥12 hours, but did not affect body fat.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

Trends in adjusted obesity prevalence increased over 20 years, particularly in adolescents from low-socioeconomic status households.

Preventable factors including obesity, hypertension, and physical activity are disparately impacting the rate of dementia among people of color.

Vaccine effectiveness was slightly lower in patients with underweight, who also have the lowest levels of vaccine uptake across all ages.

The approval, which was was supported by data from a 56-week trial involving 223 obese individuals 12-17 years old, recommended the capsules be used in conjunction with a reduced-calorie diet and increased physical activity.

A look into the top discussions on the management of obesity at the 2022 OMA Spring Meeting, from new agents to treating special populations.

Dr. Auriemma examines recent paradigm shifts in obesity care, from new pharmacotherapy options to the important role of stakeholders in reducing rates.

Patients with obesity who had bariatric surgery had lower rates of mortality compared to patients who did not have bariatric surgery.

The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.

The FDA-approved sleep agent was associated with ≥5% weight loss in more than one-quarter of patients in a phase 3 trial.

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.

Both the regulation of cues intervention and ROC with behavioral weight loss were found successful in individuals with high levels of food responsiveness.

Adolescents with a GLP-1 RA prescription within year of T2D diagnosis were more probable to be in better glycemic control and less probable to be prescribed insulin.

A continued discussion into misconceptions surrounding obesity treatments and how to better empower patients seeking out treatment.

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

A discussion into available pharmacotherapy for obesity and the uptake in practice of newer agents.

Jennifer Green discussed weight management and obesity during the annual Pri-Med West conference.

Type 2 diabetes can be more aggressive in younger patients.